COMMUNIQUÉS West-GlobeNewswire

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
10/04/2025
DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading [...]
Avalyn to Participate in Upcoming Investor Conference in April
10/04/2025
CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, [...]
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
10/04/2025
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE [...]
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors
10/04/2025
Dansey, a former senior executive at Pfizer and Seagen, Inc., brings extensive experience in immuno-oncology and drug development Board appointment reinforces Company’s commitment to advancing Jankistomig, a one-of-a- [...]
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
10/04/2025
Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announces today the [...]
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
10/04/2025
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
10/04/2025
A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in Indonesia and [...]
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
10/04/2025
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both [...]
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
10/04/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting
10/04/2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ace Vision Group, Inc . (“AVG” or “the Company”), an emerging medical device company on the forefront of pioneering a laser microporation therapy for the aging eye, today [...]
Glass House Brands and Eaze Partner to Launch PLUS Cannabis Gummies in Florida
10/04/2025
LONG BEACH, Calif. and TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
10/04/2025
– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE [...]
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
10/04/2025
Highlights will include data from non-clinical and real-world patient use BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies [...]
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
10/04/2025
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
10/04/2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple [...]
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
10/04/2025
– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT’s) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ( [...]
Large Reductions in Suicide Risk, Attempts and Deaths Demonstrated by Three “Real World” Studies in Primary Care
10/04/2025
Shatterproof and The Bowman Family Foundation call for widescale adoption of Collaborative Care Model in primary care to reduce suicide rates and lower total healthcare costs for payers NORWALK, Conn., April 10, 2025 ( [...]
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
10/04/2025
LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of [...]
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
10/04/2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]

Pages